The transcription factor GLI2 has an important role in the transduction of Hedgehog signaling and thereby regulates tumorigenesis in a wide variety of human tumors. However, the mechanisms controlling GLI2 protein expression and stabilization are incompletely understood. In this study, we show that the mitogen-activated protein kinase MEK1 modulates GLI2 both at the mRNA and protein level. Constitutively activated MEK1 prolonged the half-life of GLI2 and increased its nuclear translocation, accompanied by attenuated ubiquitination of GLI2 protein. RSK2, a protein kinase lying downstream of MEK-ERK cascade, mimicked the effect of MEK on GLI2 stabilization. MEK1 and RSK2 failed to augment the half-life of GLI2 lacking GSK-3b phosphorylation sites, indicating that MEK-RSK stabilizes GLI2 by controlling targeting GSK-3b-mediated phosphorylation and ubiquitination of GLI2. The significance of MEK-RSK stabilization was demonstrated in experiments showing that activation of MEK-RSK paralleled higher protein level of GLI2 in several multiple myelomas (MM) cells relative to normal B cells. Moreover, combined treatment with RSK and GLI inhibitors led to an enhanced apoptosis of MM cells. Thus, our results indicate that MEK-RSK cascade positively regulates GLI2 stabilization and represses its degradation via inhibiting GSK-3b-dependent phosphorylation and ubiquitination of GLI2.
INTRODUCTION
The Hedgehog (Hh) signaling has crucial roles in embryonic development, tissue patterning, organogenesis, as well as maintenance of stem cells in adult tissues.
1,2 Dysregulation of Hh signaling has been implicated in several disparate human cancers. 3, 4 Activation of Hh signaling is initiated by the binding of Hh ligands to a transmembrane domain protein receptor patched (PTCH), thereby releasing the inhibition of smoothened by PTCH. 5 Activation of smoothened eventually results in an accumulation of activator forms of the GLI zinc finger transcription factors (GLI1 and GLI2, GLI3 acts as a repressor), as well as the nuclear localization of the GLI transcription factors and expression of GLI-target genes. 6 The full-length forms of these GLIs can be modulated into activators and repressors, GLI A and GLI R , respectively. The Hh signaling pathway ultimately exerts its effects by influencing the balance between GLI A and GLI R . 7 GLI1 acts primarily as a constitutive activator of Hh target genes because the protein lacks a repressor domain and is not proteolyticly processed. 8 GLI3 and, to a lesser extent, GLI2 are processed into GLI R , whereas all three GLI proteins contribute to GLI A . In the absence of Hh ligands, GLIs are constitutively cleaved into a truncated repressor form in a site-specific manner by the proteasome after its sequential phosphorylation by PKA, CK1 and GSK-3b and subsequent ubiquitination by b-TrCP ubiquitin E3 ligase. GLI2 full-length protein is readily degraded in an ubiquitinproteasome-dependent manner following its phosphorylation by PKA. 9, 10 Ample evidence indicates that aberrant activation of GLIs may trigger cell transformation and oncogenesis, and numerous reports have revealed that GLI2 has a dominant role in these pathologic processes. 11, 12 As the GLI2 full-length protein is subject to degradation by the proteasome, stabilizing full-length form of GLI2 is required for its activation, accumulation in the nucleus and execution of transcriptional events. Therefore, understanding GLI2 stabilization and activation may lead to novel and useful strategies for tumor therapy. 13 Currently, little is known about the molecular mechanisms regulating GLI2 stabilization. In this study, we investigated the effect of MEK-RSK cascade on GLI2 stabilization. We found that the half-life of GLI2 protein was significantly prolonged by activation of MEK1. Cellular fractionation experiments showed that the magnitude of GLI2 stabilization was greater in the cytosol than in the nucleus. Immunofluorescence study of protein localization showed increased GLI2 protein in the nucleus in response to overexpression of MEK1. Mechanistic studies showed that activation of the MEK-RSK2 axis phosphorylated GSK-3b at the Ser 9site, which in turn led to GSK-3b inactivation and subsequent GLI2 hypoubiquitination. The significance of these results is supported by results showing that multiple myeloma (MM) cells exhibit higher activation levels of MEK-RSK signaling than the normal B cells, and showed higher protein level of GLI2 with lower ubiquitination status. Moreover, a synergistic effect on MM cell apoptosis was induced by combination of GLI and RSK inhibitors, which suppressed Hh transcriptional activity and Hh target gene expression. Taken together, our study indicates that MEK1-RSK2 cascade contributes to Hh signaling activation and suggests a rational therapeutic target for MM treatment.
RESULTS

MEK1 stabilizes the full-length protein of GLI2 transcription factor
To evaluate the effects of MEK1 on the transcription factor GLI2, we examined the transcriptional activity, mRNA level and protein level of GLI2 in an Hh-responsive HEK293 cells. The HEK293 cells were transfected either with a luciferase reporter under the control of eight tandem copies of GLI-binding site (8 Â GBSluciferase), or with a m8 Â Gli-Luciferase (mutated Gli sites) mutant, together with different ratio of plasmids encoding a constitutively activated MEK1 (ratio of constitutively active MEK (caMEK1)/GLI-Luc ¼ 1:1, 2:1, 3:1) for 24 h. The normalized GLIluciferase activity of 8 Â GBS-luciferase was increased 4-10 folds by caMEK1 in a dose-dependent manner, whereas the activity of the m8 Â Gli-Luciferase mutant had no significant change (Figure 1a ). Additionally, the mRNA level of GLI2 was also upregulated up to 16-fold at maximal caMEK1 concentrations when detected with real-time PCR (Figure 1b) . These results appear to be independent of GLI1 as demonstrated by knockdown of GLI1 by GLI1-small hairpin RNA (Supplementary Figure 1) . Knockdown of GLI1 had little effect on GLI-luciferase, which , and the decay curves by densitometric calculation generated with averaged values from at least three experiments to determine the half-life of exogenous GLI2-flag (e) and endogenous GLI2 (f ) proteins; (g) and (h) indicated the significant differences in half-lives of exogenous and endogenous proteins treated differently. **Po0.001. caMEK1, constitutively active MEK1; CHX, cycloheximide.
indicated that activation of GLI-luciferase by caMEK1 was GLI2 specific (Supplementary Figure 1) .
We determined the half-life of GLI2 protein in the presence and absence of caMEK1 plasmids. Half-life of GLI2-flag was extended from 0.9 ± 0.2 h to 3.5 ± 0.5 h in the presence of caMEK1. Addition of the MEK inhibitor, U0126 at the concentration of 10 mM, diminished the effect of caMEK1 on GLI2 stabilization, and the half-life was reversed to the same as vector control (Figures 1c, e and g). Further investigation found caMEK1 also stabilized endogenous GLI2, because half-life of GLI2 was extended from 1.05 ± 0.3 h to 3.8±0.4 h owing to caMEK1 overexpression, and this effect also reversed by treatment of U0126 (Figures 1d, f and h). We also confirmed these results using another MEK1 specific inhibitor, the PD98059, and the same results were obtained (data not shown).
To determine if the effect of MEK1 on GLI2 protein was specific to specific intracellular compartments, we determined the half-life in different cell extracts. Our results showed caMEK1 mainly extended the half-life of GLI2 in the cytoplasm. The half-life of GLI2 in the cytoplasm increased from 0.35±0.08 h to 2.8±0.3 h, which was more than eightfold (Po0.001) (Figures 2a, b and c) . By contrast, the GLI2 protein in the nucleus was more stable than that in the cytoplasm and was less dependent on caMEK1. The half-life of nuclear protein increased o2-fold (6.3±0.8 h to 11.8±1.3 h, Po0.05) (Figures 2d, e and f).
MEK1 facilitates GLI2 cyto-nuclear translocation To investigate whether the subcelluar localization of GLI2 is modulated by MEK1, we next examined the distribution of the GLI2-flag protein in subcellular locations. As shown in Figure 3a , GLI2-flag protein mainly expressed in the cytoplasm in the absence of caMEK1 (upper lane); however, overexpression of caMEK1, drove most of GLI2 protein into the nucleus (middle lane). Addition of the MEK inhibitor U0126 suppressed the nuclear distribution of GLI2 proteins (lower lane). We quantified the cells into three groups depending on GLI2-flag subcellular location, in cytoplasm, in nucleus or both to analyze the significance. The quantification data demonstrated that GLI2-flag was dominantly seen in the cytoplasm without caMEK1 (48 ± 18% cytoplasm-GLI2 cells versus 17 ± 9.5% nucleus-GLI2 cells per vision field, Po0.001); when caMEK1 was overexpressed, GLI2-flag was mainly seen in the nucleus rather than cytoplasm (7 ± 5.2% cytoplasm-GLI2 cells versus 45 ± 14% nucleus-GLI2 cells per vision field, Po0.001). However, when the MEK inhibitor U0126 was presented with caMEK1, the ratio of the cytoplasm-GLI2 and nucleus-GLI2 cells was almostly equivalent to the vector control group (48 ± 18% versus 43 ± 7.2% for the cytoplasm-GLI2 cells, and 17 ± 9.5% versus 13±7% for the nucleus-GLI2 cells, respectively, P40.05) (Figure 3b) . Using western blot, we found the nuclear accumulation of GLI2-flag protein due to caMEK1 overexpression was significantly higher than vector control, but the accumulation was attenuated by MEK inhibitor 10 mM of U0126 (Figures 3c and d) or 5 mM of PD98059 (data not shown).
MEK1 regulates GLI2 activation by alleviating ubiquitination through MEK1-RSK2 cascade To evaluate the effect of MEK1 on GLI2 ubiquitination, we expressed GLI2-flag protein in HEK293, with HA-ubiquitin in the presence or absence of caMEK1. Significantly, overexpression of caMEK1 attenuated GLI2 ubiquitination compared with vector control. Moreover the inhibitor U0126 reversed this effect of MEK1 (Figure 4a ). We also examined the effects of MSK1, RSK1 and RSK2 in this study, and our results showed that RSK1 only had weak protective effect on GLI2 stabilization, but RSK2 mimicked the effect of MEK1 proximally (Figure 4b ). Conversely, MSK1 failed to protect GLI2 from degradation. Furthermore, expression of a constitutively active form of RSK2 resulted in even greater GLI2 protein. The N-terminal truncation mutant RSK2, HA-RSK2 DN (DN), did not promote GLI2 protein accumulation. To confirm this result, we used another source of RSK2 plasmids 14 with similar result (Figure 4b ). These data illustrate that RSK2 rather than MSK1 was the key modulator activated by MEK1 to regulate GLI2 stabilization. Subsequently, immunoprecipitation assays demonstrated that both the HA-RSK2 and GFP (green fluorescent protein)-RSK2 constructs induced hypoubiquitination of GLI2 protein like caMEK1 (Figure 4c) . Moreover, the constitutively active mutant of RSK2, both the HA-RSK2 amino acid and GFP-RSK2 amino acid, downregulated the ubiquitination status of GLI2 protein much greater than the wild-type protein. Taken together, these results indicate that RSK is a crucial factor in MEK1-mediated GLI2 stabilization through repressing the ubiquitination of GLI2.
As we did not observe a direct interaction between RSK2 and GLI2 (data not shown), we hypothesized that GSK-3b, a negative regulator of GLI2, may serve as the target of RSK2 and affects GLI2 stabilization. Our results showed that RSK2 regulated the phosphorylation status of GSK-3b (Figure 5a) , and a GSK-3b phosphorylation sites mutated GLI2, GSM, was not protected by RSK2 (Figure 5b ), which indicated that RSK promoted GLI2 stabilization via inhibiting GSK-3b-mediated GLI2 phosphorylation. To confirm this, we detected the ubiquitination of GLI2 following GSK-3b overexpression or knockdown, and found that overexpression of GSK-3b downregulated the GLI2 protein level and upregulated the ubiquitination of GLI2, especially the nonrepressible mutant of GSK-3b (GSK-3b amino acid) (Figure 5c ). By contrast, knockdown of GSK-3b with GSK-3b-specific small hairpin RNA, attenuated the ubiquitination of GLI2 significantly and upregulated GLI2 protein (Figure 5d) . A densitometry measurement was also used to analyze the protein levels above, and results showed a significant change compared with control groups (Supplementary Figure 2) . MEK-RSK signaling contributes to Hh signaling in MM As Hh signaling is abnormally activated in MM, 15 we examined GLI2 protein half-life in several myeloma cell lines. Significantly, we found the half-lives of GLI2 protein in the ARP-1, MM.1s, RPMI8226 and U266 myeloma cells were all significantly longer than the normal level (Figures 6a and b) . Interestingly, we also found that prolonged half-life of GLI2 in these myeloma cells was correlated with a higher activation status of MEK/RSK signaling than normal B cells (Figure 6c ) and that the ubiquitination status of GLI2 was low (Figure 6d ). We also found the overwhelming majority of GLI2 was localized in the nucleus rather than in the cytoplasm in these myeloma cells (Figure 6e ), which further supported the abnormal hyperactivity of Hh signaling in MM. To investigate the contribution of RSK and GLI to myeloma cell survival, we tested whether the RSK inhibitor, SL0101, and the GLI inhibitor GANT58altered GLI transcriptional activity and myeloma cell survival. ARP-1 myeloma cells treated with 10 mM of SL0101 or 10 mM of GANT58 exhibited synergetic suppression of GLIluciferase activity and diminished mRNA of Hh-signaling target genes, GLI1, CCND1 and BCL2 (Figures 7a and b) . Furthermore, apoptosis of ARP-1 cells was activated following inhibition of RSK and/or GLI. Significantly, treatment of ARP-1 cells with 10 mM of SL0101 or 10 mM of GANT58 induced apoptosis of only 15-20% of the cells. By contrast, simultaneous application of both inhibitors induced apoptosis of 55% of the cells (Figure 7c ). Moreover, this synergetic effect was confirmed in the cleaved poly (adenosine diphosphate-ribose) polymerase protein levels (Figure 7d 3rd  panel) detected by western blot. Correspondingly, the GLI2 protein in ARP-1 cells treated with the combination of two inhibitors was dramatically decreased compared with either one individually. BCL2, a main target of Hh signaling and acting as an antiapoptosis protein in myeloma cells, was also dramatically downregulated by the two inhibitors (Figure 7d) . Moreover, the similar results were also found in MM.1S and U266 myeloma cells MEK1-RSK2 contributes to hedgehog signaling Z Liu et al Figure 2 . Different degradation level of GLI2 protein in cytoplasm and nucleus. Cytoplasmic (a) and nuclear (c) GLI2-flag proteins were extracted sequentially for western blot assay to detect the protein degradation. The decay curves by densitometric calculation representing at least three experiments to determine the half-life of cytoplasmic (b) or nucleus (e) GLI2-flag proteins. Densitometric determination of GLI2 half-life in cytoplasm and in nuclear was analyzed and shown in (c) and (f ). *Po0.05; **Po0.001. caMEK1, constitutively active MEK1; CHX, cycloheximide. (data not shown). Taken together, our results suggested that MEK-RSK cascade stabilizes GLI2 to activate the Hh signaling via a noncanonical pathway in myeloma cells.
DISCUSSION
The current study provides new insights into non-canonical Hh activation through stabilization of the key transcription factor . Stabilization and hypoubiquitination of GLI2 correlates with GSK-3b. (a) Phosphorylation status of GSK-3b (Ser9) due to overexpression of caMEK1, RSK1, HA-RSK2 wt, HA-RSK2 DN, HA-RSK2 amino acid and MSK1 was examined in HEK293 cells by western blot, and total GSK-3b served as a control. (b) Degradation of the GLI2 protein with GSK-3b phosphorylation sites mutant, the GSM, due to overexpression of the constructs listed was examined in HEK293 cells after treatment of 20 mM of cycloheximide for 6 h. GLI2-flag protein level and ubiquitination status due to GSK-3b wild type or GSK-3b constitutively active plasmid constructs (c), GSK-3b-specific small hairpin RNA plasmid or control small hairpin RNA plasmid (d) were examined by western blot and immunoprecipitation, respectively. CHX, cycloheximide; shRNA, small hairpin RNA.
GLI2
. The results suggest a new therapeutic strategy for treatment of MM. In mammals, stabilization of GLI2 full-length protein has been implicated as a key event during the transduction of Hh signaling. 16 Forced expression of GLI2 in mouse skin by tissuespecific promoter is sufficient to develop tumor with histological and molecular characteristics of basal cell carcinoma. 17 Conversely, GLI2 knockdown reduces anchorage-independent colony formation of prostate cancer cells, invasiveness and metastases of melanoma cells, and promotes cell chemosensitivity. 18 Enhanced expression or activation of GLI2 is often detected in cancer tissues of different origin and contributes to the progression of neoplasm. For instance, elevated GLI2 expression has recently been described in basal cell carcinoma, 19 hepatocellular carcinoma 20 and melanoma, which subsequently increases the expression of its target gene, GLI1. Thus, interference with GLI2 expression or activation will be a novel and useful strategy for tumor therapy. 13 Despite this, mechanisms of GLI2 stabilization and activation, and the contribution to tumorigenesis MEK1-RSK2 contributes to hedgehog signaling Z Liu et al is poorly understood. 21 GLI2 processing is extremely complicated. For example, unlike GLI3, GLI2 has a region of 196 residues upstream of the carboxyl-terminus, named processing determinant domain. This domain determines low efficiency of GLI2 processing; hence, the vast majority of GLI2 protein exists in the full-length form and only a small fraction is present in the processed form. 22 Usually, Hh signaling attenuates GLI2 degradation in vivo, allowing cytoplasmic accumulation and nuclear import of GLI2. In addition to Hh signaling, other signaling pathways may be involved in the regulation of GLI2 stabilization. The synergy and cross talk between Hh and Wnt, Notch, RhoA, PI3K/AKT, as well as other signaling pathways has been well characterized. 23 In this study, we revealed a novel protective effect of MEK-RSK cascade on GLI2 stabilization. Our data verified that RSK but not MSK contributes to GLI2 stabilization. Overexpression of MEK1 or RSK2 attenuated the ubiquitination of GLI2 protein and extended its half-life. Inhibition of MEK-RSK cascade resulted in destabilization and degradation of GLI2. Interestingly, MSK failed to increase the half-life of GLI2. We assume that because of their respective activation mechanisms and function, MEK-RSK cascade is more highly specialized for controlling GLI2 stabilization than the p38-MSK cascade. In fact, p38 kinase primarily functions as transducers of stress response. 24 Our experiments excluded the possibility that RSK forms a complex with GLI2 to regulate the transcription of genes lying downstream of Hh signaling. Therefore, GLI2 apparently is not an optimal phosphorylation substrate of RSK. Previous publications also suggested that MEK-ERK cascade was responsible for RASinduced GLI stimulation as MEK1 or ERK1/2 inhibitors were able to block the RAS effect. 25 However, direct phosphorylation of GLI1 by ERK2 was not detected in kinase assays. Thus, we hypothesized that the MEK-RSK cascade may activate GLI2 via an indirect mechanism. Indeed, we observed that overexpression of MEK1 and RSK2 repressed GSK-3b activity, thereby preventing GSK-3b-mediated phosphorylation and subsequent ubiquitinproteasome-dependent degradation of GLI2. Collectively, our finding indicated that MEK-RSK cascade can stabilize GLI2 protein to amplify the effect of Hh signaling via inhibition of GSK-3b activity.
Most importantly, our finding emphasizes a possibility that MEK-RSK cascade may synergize with Hh signaling to exert their effect on tumor proliferation and malignancy. Recent publications suggest other pathways such as EGF, FGF, as well as TGF-b signaling can induce the transcription or stabilization of GLIs, and served as non-canonical Hh pathway activation. 26 Combined with previous research, our data demonstrate that GLI2 functions as an information nexus at the convergence of different signal inputs from ERK and Hh pathways. Therefore, our study underlines a molecular basis of therapeutic interference for tumors relying on Hh/GLI2 and MEK-RSK signaling. In support of this, we evaluated the pharmacologic effects of the Hh pathway inhibitor, GANT58, and RSK inhibitor, SL0101, as a single agent or in combination on myeloma cell survival. Interfering with RSK function using SL0101 accelerated GLI2 degradation and reduced the expression of GLI2 target genes. The combination of both inhibitors efficiently yielded a proapoptotic effect. Therefore, our study not only highlights the complexity of Hh/GLI2 signaling activation, but also sheds light on the development of therapeutic strategies for myeloma.
MATERIALS AND METHODS
Reagents and plasmids
MEK inhibitor U0126 and PD98059, the cyclopamine, the protein cycloheximide, the GLI inhibitor RANT58, the MG132, the anti-FLAG M2 antibody and mouse anti-HA antibody were purchased from Sigma-Aldrich (St Louis, MO, USA); phospho-MEK1/2 antibody (Ser217/221), phospho-ERK1/2 (T202/Y204) antibody and GSK-3b (Ser9) antibody were purchased Figure 7 . Synergy effect in MM cell apoptosis induced by inhibition of GLI2 and RSK. The ARP-1 cells transfected with 8 Â GLI-Luciferase reporter plasmid were treated with 10 mM of GANT58, 10 mM of SL0101, separately or combined for 24 h and then processed for luciferase activity assay (a), or for real-time PCR assay (b), or 48 h for apoptosis assay using FACS with Annexin V antibody (c) and western blot assay to detect the protein level of GLI2, BCL2, as well as the cleaved poly (adenosine diphosphate-ribose) polymerase (d). *Po0.05;**Po0.001. DMSO, dimethyl sulfoxide.
